+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nanomedicine for Ischemic Cardiomyopathy

  • ID: 4829339
  • Book
  • May 2020
  • Region: Global
  • 214 Pages
  • Elsevier Science and Technology
1 of 3

Nanomedicine for Ischemic Cardiomyopathy: Progress, Opportunities, and Challenges provides an overview on the recent advances in diagnostic and treatment of ischemic cardiomyopathy diseases including myocardial infarction. Shortcomings of the current methods and how nanomedicine can address those obstacles in the field are discussed including the limitations of newly developed cell therapy approaches to clinical translation and how nanomedicine may overcome crucial issues and facilitate the successful and efficient clinical translation of cell therapy. Biomolecular therapy is also explored as another powerful approach for regeneration of heart tissue including available methods and systematic delivery of biomolecules using nanocarriers to the injured part of myocardium through active targeting. Finally, coverage of major tissue engineering advances for myocardial regeneration, including use of epicardial nanostructured patches for regeneration of injured epicardium and the highly conductive patches for enhancing cross talks between the cardiomyocytes, is explored. This concise, yet rigorous coverage, of the field of cardiac nanotechnology outlines the innovative and necessary role of nanomedicine in regenerative medicine for cardiac repair allowing researchers, clinicians, and nanotechnologists to examine the strengths and limitations of current findings and predict future trends to advance the applications of nanotechnology in cardiovascular biomedical research.

  • Introduces concepts of the unique capacities of cardiac-nanotechnology
  • Points to potential and promising applications of engineering nanotechnologies on revolutionizing cell therapy and biomolecular therapy approaches for cardiac regeneration
  • Bridges the knowledge gap between cardiologists and cardiac regenerative nanomedicine experts

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3
1. Ischemic cardiomyopathy: A Historical Overview
2. Nanotechnology: A Historical Overview
3. Current Clinical Strategies to Prevent Post Myocardial Infarction Heart Failure
4. Use of Nanoparticulate Systems to Salvage Myocardium
5. Use of Nanoparticulate Systems to Regenerate Myocardium
6. Future trends: Clinicians' Point of View
7. Future trends: Nanotechnologists' Point of View
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Mahmoudi, Morteza
Dr. Morteza Mahmoudi is an Assistant Professor of Radiology and Precision Health Program at Michigan State University (MSU). Prior coming to MSU, he was an Assistant Professor of Anesthesiology at Brigham and Women's Hospital, Harvard Medical School. His specific research interest is in nanomedicine and regenerative medicine for the development of new nano-based platforms for prevention/treatment of life-threatening conditions such as cardiomyopathy, cancer, and neurodegenerative diseases. Aside from nanomedicine and regenerative medicine, Dr. Mahmoudi is also very active in social sciences and specifically in drawing the attention of the scientific community in the rising issue of academic bullying. In addition, he is also working on identifying the reasons behind the enormous disparity between the numbers of major prize winners between the sexes (which currently stands at more than an order of magnitude in favor of male nominees) and seek to draw the attention of award agencies, researchers, entrepreneurs, and media to reexamine the historical imbalances between the sexes in winning major scientific awards. He is among 2018 highly cited researchers in 2018 as reported by Clarivate Analytics.
Note: Product cover images may vary from those shown
Adroll
adroll